BIOPLUS-INTERPHEX KOREA (BIX) 2026 is Korea's premier biopharmaceutical business event, bringing together global leaders across the entire biopharmaceutical value chain. Scheduled to take place from October 28-30, 2026, at COEX, Seoul, South Korea, the event serves as a platform for innovation, knowledge exchange, technology showcase, and strategic business partnerships.
From drug discovery and clinical development…
An Interview with Priyanka Joshi, Associate Scientist in Analytical Development
Introduction
Cancer remains one of the world's greatest healthcare challenges, driving scientists to develop more effective and precise treatment approaches. Among the most promising innovations are cell therapies, which harness the body's own immune system to fight cancer. Behind these advances are scientists working to…
Shots
Breztri Aerosphere became the first and only fixed-dose triple-combination maintenance therapy approved in the US for asthma patients aged 12 years and older, expanding beyond COPD and reinforcing the role of single-inhaler triple therapy in advancing asthma care.
The approval strengthens AstraZeneca’s respiratory portfolio and long-term vision of transforming care beyond symptom control, with additional regulatory reviews…
Shots:
A UK observational study spanning 17 years shows a 2.9-fold increase in Cardiac Amyloidosis diagnoses, highlighting significant progress in awareness among healthcare professionals and advancements in diagnostic tools
The study underscores the importance of improving the identification and treatment of Cardiac Amyloidosis, particularly in cases with overlapping conditions such as heart failure
Mina Makar,…

